We are live on ! Find out more
INBX icon

Inhibrx

88 hedge funds and large institutions have $149M invested in Inhibrx in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 34 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1% less capital invested

Capital invested by funds: $151M → $149M (-$2.03M)

2.43% less ownership

Funds ownership: 74.52%72.09% (-2.4%)

4% less funds holding

Funds holding: 9288 (-4)

29% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 14

35% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 34

Holders
88
Holders Change
-4
Holders Change %
-4.35%
% of All Funds
1.16%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
10
Increased
22
Reduced
34
Closed
14
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
US Bancorp
101
US Bancorp
Minnesota
-$224 -16 Closed
Jones Financial Companies
102
Jones Financial Companies
Missouri
-$56 -4 Closed

INBX Hedge Fund Activity: Q2 2025 in Review

88 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q2 2025, worth a combined $149M — down 1.3% from $151M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of INBX and 10 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 22 added.

The largest buyer was Woodline Partners, adding an estimated $3.94M. The largest seller was PFM Health Sciences, cutting an estimated $2.52M.

  • 88 institutional investors held Inhibrx (INBX) as of Q2 2025, down from 92 in Q1 2025.
  • Funds reported $149M of Inhibrx stock for Q2 2025, down 1.3% quarter-over-quarter.
  • 10 funds opened new Inhibrx positions in Q2 2025 and 14 closed out, a net change of -4 holders.
  • The largest Inhibrx buyer in Q2 2025 was Woodline Partners, an estimated $3.94M added.
  • The largest Inhibrx seller in Q2 2025 was PFM Health Sciences, an estimated $2.52M sold.

Based on aggregated 13F filings for Q2 2025.